PD-1Hi CAR-T cells provide superior protection against solid tumors
Chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising treatment option for several hematologic cancers. However, efforts to achieve the same level of therapeutic success in solid tumors have largely failed mainly due to CAR-T cell exhaustion and poor persistence at the tumor site...
Main Authors: | Cooper J. Sailer, Yeonsun Hong, Ankit Dahal, Allison T. Ryan, Sana Mir, Scott A. Gerber, Patrick M. Reagan, Minsoo Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1187850/full |
Similar Items
-
Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics
by: Emanuela Guerra, et al.
Published: (2021-12-01) -
New developments in immunotherapy for lymphoma
by: Benjamin Heyman, et al.
Published: (2018-09-01) -
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-01-01) -
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
by: Yanna Lei, et al.
Published: (2021-03-01) -
Mechanisms of CAR T cell exhaustion and current counteraction strategies
by: Xiaoying Zhu, et al.
Published: (2022-12-01)